anti-EpCAM bispecific T-cell engager-secreting anti-HER2 CAR T-cell therapy (Fate Therapeutics)

N/A

ๆŠฅๅ‘Šๆ—ถ้—ด: 2026/03/26 20:00:17

ๅŸบๆœฌไฟกๆฏ

่ฏ็‰ฉๅ็งฐanti-EpCAM bispecific T-cell engager-secreting anti-HER2 CAR T-cell therapy (Fate Therapeutics)
่ฏ็‰ฉๅˆซ็งฐN/A
่ฏ็‰ฉ็ฑปๅž‹็”Ÿ็‰ฉ่ฏ > ่›‹็™ฝ็ฑป่ฏ็‰ฉ > ๅ…็–ซ็ƒ่›‹็™ฝ > ๆŠ—ไฝ“ > ๅ•ๅ…‹้š†ๆŠ—ไฝ“ > ๅคš็‰นๅผ‚ๆ€งๅ•ๅ…‹้š†ๆŠ—ไฝ“ > ๅŒ็‰นๅผ‚ๆ€งๆŠ—ไฝ“็ป†่ƒžไธŽๅŸบๅ› ็–—ๆณ• > ็ป†่ƒž็–—ๆณ• > ๅ…็–ซ็ป†่ƒž็–—ๆณ• > ๆท‹ๅทด็ป†่ƒž็–—ๆณ• > T็ป†่ƒž็–—ๆณ• > ๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“T็ป†่ƒž็–—ๆณ•๏ผˆCAR-T๏ผ‰็”Ÿ็‰ฉ่ฏ > ่›‹็™ฝ็ฑป่ฏ็‰ฉ > ้‡็ป„่›‹็™ฝ > ่žๅˆ่›‹็™ฝ +[4]ย 
ไฝœ็”จๆœบๅˆถไธŠ็šฎ็ป†่ƒž็ฒ˜้™„ๅˆ†ๅญ่ฐƒ่Š‚ๅ‰‚ๅ—ไฝ“่›‹็™ฝ้…ชๆฐจ้…ธๆฟ€้…ถ erbB-2่ฐƒ่Š‚ๅ‰‚
้ถ็‚นไธŠ็šฎ็ป†่ƒž็ฒ˜้™„ๅˆ†ๅญๅ—ไฝ“่›‹็™ฝ้…ชๆฐจ้…ธๆฟ€้…ถ erbB-2
ๆฒป็–—้ข†ๅŸŸ / ้€‚ๅบ”็—‡ๅฎžไฝ“็˜ค
ๅ…จ็ƒๆ‰นๅ‡†้€‚ๅบ”็—‡N/A
ไธญๅ›ฝๆ‰นๅ‡†้€‚ๅบ”็—‡N/A
้ฆ–ๆ‰นๅ›ฝๅฎถ/ๅŒบๅŸŸN/A
้ฆ–ๆ‰นๆ—ฅๆœŸN/A
ๅ›ฝๅฎถ/ๅŒบๅŸŸ็พŽๅ›ฝ
ๆ˜ฏๅฆๅคๆ–นๅฆ
ๅ…จ็ƒๆœ€้ซ˜็ ”ๅ‘็Šถๆ€ไธดๅบŠๅ‰
ไธญๅ›ฝๆœ€้ซ˜็ ”ๅ‘็Šถๆ€N/A
ๅŽŸ็ ”ๅ…ฌๅธFate Therapeutics Inc
ๆณจๅ†Œๅˆ†็ฑปN/A

็ ”ๅ‘ไฟกๆฏ

ๆดป่ทƒๅ…ฌๅธFate Therapeutics Inc
้žๆดป่ทƒๅ…ฌๅธN/A
ๆดป่ทƒ้€‚ๅบ”็—‡ๅฎžไฝ“็˜ค
้žๆดป่ทƒ้€‚ๅบ”็—‡N/A

ๅ…ถไป–ไฟกๆฏ

ATCไปฃ็ N/A
็›ธๅ…ณ้“พๆŽฅN/A